Pluristem Therapeutics (NASDAQ:PSTI) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Pluristem Therapeutics (NASDAQ:PSTIGet Rating) in a research report report published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Alliance Global Partners cut their price target on Pluristem Therapeutics from $9.50 to $4.00 and set a buy rating for the company in a research note on Wednesday, July 20th.

Pluristem Therapeutics Stock Performance

The firm has a market capitalization of $32.35 million, a P/E ratio of -0.68 and a beta of 1.91. The company has a current ratio of 8.22, a quick ratio of 8.22 and a debt-to-equity ratio of 0.57. Pluristem Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $3.45. The firm has a 50 day simple moving average of $1.27 and a two-hundred day simple moving average of $1.62.

Pluristem Therapeutics (NASDAQ:PSTIGet Rating) last released its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter. Sell-side analysts predict that Pluristem Therapeutics will post -1.02 EPS for the current year.

Institutional Trading of Pluristem Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Green Alpha Advisors LLC increased its position in Pluristem Therapeutics by 16.7% during the 1st quarter. Green Alpha Advisors LLC now owns 78,159 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 11,200 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Pluristem Therapeutics during the 4th quarter worth about $62,000. Jane Street Group LLC increased its position in Pluristem Therapeutics by 74.7% during the 1st quarter. Jane Street Group LLC now owns 137,468 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 58,764 shares in the last quarter. Nia Impact Advisors LLC increased its position in Pluristem Therapeutics by 11.3% during the 1st quarter. Nia Impact Advisors LLC now owns 837,898 shares of the biotechnology company’s stock worth $1,734,000 after purchasing an additional 85,024 shares in the last quarter. Finally, TownSquare Capital LLC purchased a new stake in Pluristem Therapeutics during the 1st quarter worth about $50,000. Hedge funds and other institutional investors own 16.94% of the company’s stock.

About Pluristem Therapeutics

(Get Rating)

Pluristem Therapeutics Inc operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.